NSG 520 Unit 4 Receptor Distribution Study Example

Course	NSG 520 Pathophysiology and Pharmacology
Unit	Unit 4
Paper type	Receptor distribution study
Length	About 950 words, 6 pages
Format	APA 7 student paper
School	Herzing University
Program	MSN
Updated	October 2026

Free sample paper for NSG 520 Unit 4

One Map, Every Effect: Deriving the Wanted and Unwanted Effects of Angiotensin Receptor Blockers From Where the AT1 Receptor Sits

Student Name

Department of Nursing, Herzing University

NSG 520: Pathophysiology and Pharmacology

Instructor Name

February 11, 2026

What this page is doingThe title states the method: derive every effect from the receptor's locations. A drug class whose benefits and harms come from the same receptor in different tissues is best understood from the map, and the title commits the paper to drawing it.

One Map, Every Effect: Deriving the Wanted and Unwanted Effects of Angiotensin Receptor Blockers From Where the AT1 Receptor Sits

The Receptor and Its Normal Role

Angiotensin II acts mainly through the angiotensin II type 1 receptor, a G protein-coupled receptor that, when activated, signals through Gq to raise intracellular calcium and activate protein kinase C, among other pathways. Its normal role is to defend blood pressure and circulating volume: when perfusion falls, the renin-angiotensin system generates angiotensin II, which acts on type 1 receptors throughout the body to constrict vessels, retain sodium and water, and preserve filtration. Angiotensin receptor blockers, such as losartan and valsartan, bind the type 1 receptor and block angiotensin II from activating it (Burnier & Brunner, 2000). Everything the class does, wanted and unwanted, follows from blocking this receptor in each tissue where it sits. Mrs. D., the composite patient with diabetes and chronic kidney disease, provides the clinical frame.

The Map, Tissue by Tissue

The table sets each location of the receptor beside what activation does there and what blockade therefore produces.

Where the receptor sits	What activation does	What blockade produces	Wanted or unwanted
Vascular smooth muscle of arterioles	Constriction, raising peripheral resistance	Vasodilation, lower blood pressure	Wanted; orthostatic dizziness is the unwanted edge
Efferent arteriole of the glomerulus	Constriction, maintaining glomerular pressure and filtration when perfusion falls	Lower intraglomerular pressure, less albuminuria, an initial fall in filtration	Wanted in diabetic kidney disease; harmful when perfusion depends on it
Adrenal zona glomerulosa	Aldosterone release	Less aldosterone, less sodium retention and potassium excretion	Mixed: helps blood pressure, raises potassium
Proximal tubule	Sodium reabsorption	Mild natriuresis	Wanted
Heart and cardiac fibroblasts	Hypertrophy and fibrosis	Less remodeling	Wanted in heart failure and hypertension
Brain	Thirst, vasopressin release, sympathetic outflow	Reduced thirst and sympathetic drive	Largely wanted
Fetal kidney	Supports kidney development and perfusion	Impaired fetal kidney function	Unwanted; contraindicated in pregnancy

Deriving the Wanted Effects

Lower blood pressure comes from blockade in arterioles, with a contribution from reduced aldosterone and sodium retention. Kidney protection in Mrs. D.'s diabetic kidney disease comes from the efferent arteriole: blocking constriction there lowers the pressure inside the glomerulus, which reduces the stress on the filtration barrier and the leak of albumin. Reduced cardiac remodeling in heart failure comes from blockade in the heart itself. These are three different benefits from one receptor in three places.

What this page is doingEach effect is derived from a specific location on the map, including effects that are wanted in one patient and harmful in another. Listing effects from a reference would not show why the same drug protects Mrs. D.'s kidneys and endangers a volume-depleted patient's.

Deriving the Unwanted Effects From the Same Map

The initial rise in creatinine: blocking efferent constriction lowers filtration at first. A rise of up to about 30% after starting a renin-angiotensin system blocker is generally consistent with this expected hemodynamic effect and is associated with long-term kidney protection rather than injury (Bakris & Weir, 2000). A larger rise suggests that filtration depended heavily on efferent constriction, as in dehydration, heart failure with low output, or narrowing of both renal arteries.

Acute kidney injury in volume depletion: when a patient on an angiotensin receptor blocker becomes dehydrated, the efferent arteriole cannot constrict to hold filtration up, and filtration can fall sharply. This is why patients are taught to hold the drug on sick days with vomiting or diarrhea.

Hyperkalemia: from the adrenal gland. Less aldosterone means less potassium secretion in the collecting duct. The risk is greatest in patients with reduced kidney function, like Mrs. D., and in those taking other drugs that raise potassium.

Fetal toxicity: from the fetal kidney, where the renin-angiotensin system supports development and perfusion. Exposure during the second and third trimesters can cause oligohydramnios, fetal kidney failure, and death, which is why the class is contraindicated in pregnancy. Studies of exposure in the first trimester have raised questions about malformations as well, though the findings have been debated (Cooper et al., 2006). Women of childbearing potential need contraception counseling.

What the Map Does Not Contain, and Why That Matters

Angiotensin-converting enzyme inhibitors reduce angiotensin II by a different route, and the enzyme they inhibit also breaks down bradykinin. Bradykinin accumulation explains the dry cough and the higher rate of angioedema with those drugs. The type 1 receptor map does not include bradykinin, so angiotensin receptor blockers cause little cough and less angioedema. This is the practical reason a patient who coughs on lisinopril can often be switched to losartan, and it is predicted by where each drug acts rather than memorized as a list of side effects.

The Second Receptor Subtype

Angiotensin II also binds a type 2 receptor, which in adults is expressed at lower levels and whose effects often oppose those of the type 1 receptor, including vasodilation and antiproliferative signaling. Angiotensin receptor blockers are selective for the type 1 receptor. When they block it, angiotensin II levels rise, because the feedback that normally suppresses renin is interrupted, and some of that extra angiotensin II acts on the unblocked type 2 receptor. Whether this contributes meaningfully to the class's benefits in people remains uncertain, and the map in this study does not depend on it. It is worth noting because it is one way in which receptor blockade differs from lowering angiotensin II production with an enzyme inhibitor: the two classes reach the same type 1 receptor effects by different paths, and leave the rest of the system in different states.

Differences Within the Class

All angiotensin receptor blockers share the map, so their effects are broadly the same. They differ in how tightly and how long they bind the receptor, in whether they are prodrugs, and in how they are cleared. Losartan, for example, is converted in the liver to a more potent active metabolite, while others act directly. Some are cleared largely by the liver and others partly by the kidney, which matters in advanced kidney disease. These differences affect dosing frequency and interactions, but not the fundamental tradeoff the map describes: every agent that blocks the type 1 receptor in the efferent arteriole will lower glomerular pressure, and every one that blocks it in the adrenal gland will tend to raise potassium.

Applying the Map to Mrs. D.

Mrs. D. takes lisinopril; if she developed a cough, a switch to an angiotensin receptor blocker would keep the efferent arteriole benefit while removing the bradykinin effect. Either way, the map tells the monitoring plan: creatinine and potassium within two to four weeks of starting or increasing the dose, blood pressure standing as well as seated, sick-day rules for dehydration, and potassium watched especially closely now that finerenone has been added, since both drugs reduce potassium excretion in the collecting duct.

References

Bakris, G. L., & Weir, M. R. (2000). Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Archives of Internal Medicine, 160(5), 685-693. https://doi.org/10.1001/archinte.160.5.685

Burnier, M., & Brunner, H. R. (2000). Angiotensin II receptor antagonists. The Lancet, 355(9204), 637-645. https://doi.org/10.1016/S0140-6736(99)10365-9

Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006). Major congenital malformations after first-trimester exposure to ACE inhibitors. New England Journal of Medicine, 354(23), 2443-2451. https://doi.org/10.1056/NEJMoa055202

What the NSG 520 Unit 4 instructions ask for

Unit 4 asks you to derive a drug's effects from the distribution of its target receptor. Expect to describe the receptor and its normal role, map its locations, derive wanted and unwanted effects from the map, note what the map does not include, address subtypes and class differences and apply the map to a patient. Students often ask how many tissues to include and how to show derivation. Include the tissues that explain the main clinical effects. Derivation means each effect follows from blocking the receptor in a named place. What the map leaves out explains differences between related drugs, such as cough with ACE inhibitors. Apply the map to a patient to show its use.

How the NSG 520 Unit 4 example is put together

The study opens with angiotensin II and the type 1 receptor's role in normal physiology. The table lists tissues with activation and blockade effects. The wanted effects section derives blood pressure and kidney protection from arteriole and efferent arteriole blockade. The unwanted section derives creatinine rise and hyperkalemia. The section on what the map lacks explains bradykinin and cough. The subtype section mentions the type 2 receptor. The class section notes similarities and minor differences. The patient section applies the map to a cough on lisinopril. Every effect points to a row in the table.

NSG 520 Unit 4 rubric: what full points look like

Herzing's rubric for a receptor distribution study usually covers the receptor description, the tissue map, derivation of effects, what the map excludes, subtypes and class differences and patient application. Deriving each effect from a row of the map is where most marks sit, because the course wants prediction rather than memorized lists. Map points reward tissues with activation and blockade effects stated side by side. Exclusion criteria look for bradykinin and cough explained as a difference from ACE inhibitors. Subtype points go to accurate, modest claims about the type 2 receptor. Application earns credit when the map guides a real patient decision. Class differences stated without exaggeration are often credited. A clear table helps. Te Riet's review of the renin-angiotensin system supports the map.

NSG 520 Unit 4 help: mistakes that cost points

A Unit 4 receptor study often goes wrong when side effects are listed without being derived from receptor location. Another frequent problem is missing the efferent arteriole, which explains both kidney protection and the creatinine rise. Students often attribute cough to ARBs at the same rate as ACE inhibitors. The type 2 receptor is ignored or overstated. Class differences are exaggerated. The patient application is missing. Angioedema, rarer with ARBs but possible, is left out. Pregnancy, where the drugs are avoided, is not linked to fetal kidney receptors. Finally, point every effect back to the map, because graders reward a study that predicts effects a student has not memorized.

Get a NSG 520 Unit 4 example written to your instructions

Send the Unit 4 instructions and the rubric from your NSG 520 classroom, and name the class the study should cover. We write a custom example that describes the target by function, maps distribution including the sites nobody wants reached, derives the consequences in order and leaves the labeling until last. First custom sample free, returned in 24 to 48 hours.

More NSG 520 papers and MSN samples

NSG 520 Unit 4 questions, answered

Can I just list the side effects?

A list answers a different question. The unit is asking where each effect comes from, so an unwanted effect should appear as a consequence of a site you already mapped. If an effect cannot be derived from your distribution section, either the map is incomplete or the effect works through something else, and saying which is itself worth credit.

How specific does the receptor detail need to be?

As specific as your course reading goes, and no further. Subtypes matter where they explain a difference in effect and are decoration where they do not. What earns credit is showing that a subtype difference produces a different consequence somewhere in the body, which is the point the whole derivation exists to make.

Should the study mention monitoring?

Keep it at the level of what an effect would look like if it appeared, which follows naturally from the derivation. Specific parameters, intervals and thresholds belong to current prescribing information and to the judgment of a prescriber, and a course example that starts issuing them has moved from explaining a class to instructing a reader.

Where can I find a free NSG 520 Unit 4 sample paper?

Read the complete NSG 520 Unit 4 receptor study here at no charge, every ARB effect derived from where the type 1 receptor sits. Ask for a custom study of another receptor.

Why do ARBs cause less cough than ACE inhibitors?

ACE inhibitors block breakdown of bradykinin, which builds up and causes cough; ARBs block the angiotensin receptor directly and leave bradykinin alone. This sample derives that difference from the receptor map.

NSG 520 Unit 4 receptor distribution study example